Syngene IPO gets robust response; issue subscribed 32 times

In a strong show, the Rs 550 crore IPO of biotechnology major Biocon's research arm Syngene International was over-subscribed 32.03 times on the last day of the offer today as both retail and institutional investors bid aggressively for the shares.
The company's IPO received bids for 51,24,24,840 shares as against 1,60,00,000 shares on offer, according to data available with the NSE till 1900 hrs, thus generating demand for shares worth over Rs 17,000 crore.
Syngene's public offer opened for subscription on Monday.
The price band has been fixed between Rs 240 and Rs 250 per share.
The public issue is of 2.2 crore shares (including the anchor investor portion of 60 lakh). At the given issue size, the company would raise Rs 550 crore at the upper end of the price band.

The company has raised Rs 150 crore from anchor investors.

In January, Biocon concluded a sale of 10 per cent stake in Syngene for Rs 380 crore to IVF Trustee Company. The deal had put the entire valuation of Syngene International at Rs 3,800 crore.
Last month, Syngene International had received capital markets regulator Sebi's approval to launch an initial public offer (IPO).
Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology and toxicology.
Axis Capital, Credit Suisse Securities (India) Private and Jefferies India Private are the book running lead managers to the issue.
In recent times, VRL Logistics' IPO was a top draw as the issue was subscribed over 74 times.